|
Pitfalls in Assessing Response to Treatment in MDS |
Sep 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Kidney involvement in myelodysplastic syndromes |
Jun 2024 |
Clinical Kidney Journal |
Myelodysplastic Syndromes (MDS) |
|
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes |
Sep 2019 |
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Myelodysplastic Syndromes (MDS) |
|
Silver lining: reduced relapse with chronic GVHD after transplant for MDS |
Oct 2020 |
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Graft Versus Host Disease (GVHD), Myelodysplastic Syndromes (MDS) |
|
Considerations for Drug Development in Myelodysplastic Syndromes |
Jul 2023 |
Clinical Cancer Research |
Myelodysplastic Syndromes (MDS) |
|
Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria |
Jul 2023 |
Clinical and Experimental Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
Mar 2019 |
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |
|
The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications |
Nov 2020 |
Cells |
Myelodysplastic Syndromes (MDS) |
|
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) |
Mar 2021 |
Cancers |
Chronic Myelomonocytic Leukaemia (CMML), Myelodysplastic Syndromes (MDS) |
|
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium |
Dec 2020 |
Cancer Medicine |
Myelodysplastic Syndromes (MDS) |
